A NEW study finds that H5N1 influenza viral lineages are beginning to evade human immunological defenses. This indicates current and future H5N1 viral lineages pose a greater risk to human health—including the possibility of increased transmission in humans. 1/
This new computational modeling of avian influenza variants' immunoprotein interactions reveals the H5N1 influenza virus is evolving to escape immunological defenses raised by previous infection or vaccination in mammals. 2/
This rapid adaptation means that if one makes an H5N1 vaccine with a previous vaccine candidate virus, the vaccine will have less efficacy, based on the measurements of how much the virus has evolved in recent years. 3/
The continuous transmission of H5N1 from birds to mammals and the increase in strains with immuno-evasive HA in mammals sampled over time suggest that antigenic drift is a source of zoonotic risk. 4/
Using high-performance computational modeling, the researchers documented a trend of weakening binding affinity of a wide variety of existing antibodies, collected from vaccinated and or infected hosts, against H5 viral isolates over time. 5/
In assessing the possible pandemic risk spurred by H5 bird flu spread and mutation, global researchers agree that the avian virus remains high on lists of potential pandemic agents. 6/
As of today, no human-to-human transmission has been reported. However, cattle in at least 17 states have tested positive for H5N1 in addition to millions of cases among wild birds, small mammals, commercial chickens, and other flocks. 7/
Between January 2022 and March 2025, the CDC reported:
-12,510 outbreaks among wild birds in U.S.
-51 jurisdictions w/ bird flu among wild birds.
-166,417,923 poultry affected
-70 human cases of H5N1, one fatal, in the U.S. 8/
Could this molecule be 'checkmate' for SARS-CoV-2?
A research team has developed new drug candidates major protease blockers, AVI-4516 & AVI-4773 that show great promise against SARS-CoV-2 & potentially other coronaviruses that could cause future pandemics 1/
In preclinical testing, the compounds performed better than Paxlovid against SARS-CoV-2 and the Middle East Respiratory Syndrome (MERS) virus, which periodically causes deadly outbreaks around the world. 2/
These MPro blocking compounds could inhibit coronaviruses in general, giving us a head start against the next pandemic. We need to get them across the finish line and into clinical trials. 3/
➡️ A study has found that people with pandemic chilblains have an unusually strong immune response to SARS-CoV-2, driven by overactive plasmacytoid dendritic cells (pDCs) responding to TLR7 signals. 1/
Given the essential role of type I interferon in protective immunity against SARS2 & the association of chilblains with inherited type I interferonopathies, researchers hypothesized that excessive I-IFN responses to SARS2 might underlie the occurrence of chilblains 2/
They identified a transient I-IFN signature in chilblain lesions, accompanied by an acral infiltration of activated plasmacytoid dendritic cells (pDCs). Patients with chilblains were otherwise asymptomatic or had mild disease without seroconversion. 3/
Differential DNA methylation 7 months after SARS-CoV-2 infection
A NEW study detected associations between changes in DNA methylation in individuals who had even asymptomatic or mild SARS-CoV-2 infections as compared to their household controls after 7 moths of infection 1/
Aberrant DNA methylation patterns have been linked to various diseases, including cancer and metabolic disorders.
These changes resembled patterns seen in autoimmune or inflammatory diseases, suggesting long-term epigenetic remodeling even in mild cases. 2/
This study shows that even mild or symptom-free COVID-19 infections can cause lasting changes in how certain genes are turned on or off in the body, seven months after infection. 3/
New research reveals that calming the brain's immune cells may reduce Alzheimer's disease inflammation. The study highlights the importance of norepinephrine, which could lead to more targeted, early, and personalized treatments. 1/
Norepinephrine is a major signaling factor in the brain and affects almost every cell type. In the context of neurodegenerative diseases such as Alzheimer's disease, it has been shown to be anti-inflammatory. 2/
In this study, the researchers describe how enhancing norepinephrine's action on microglia can mitigate early inflammatory changes and neuronal injury in Alzheimer's models. 3/
➡️ A NEW study finds Metformin could prevent a form of acute myeloid leukemia (AML) in people at high risk of the disease.
Researchers investigated how metformin could prevent abnormal blood stem cells w/ genetic changes from progressing to AML 1/
Metformin impacts mitochondrial metabolism, & these pre-cancerous cells need this energy to keep growing. By blocking this process, researchers stop the cells from expanding & progressing towards AML, whilst also reversing other effects of mutated DNMT3A gene 2/
Thanks to recent advances, individuals at high risk of AML can be identified years in advance using blood tests and blood DNA analysis, but there's no suitable treatment that can prevent them from developing the disease. 3/
It has been reported that repeated administration of some COVID vaccines induces high IgG4 levels.
New research revealed a surprising IgE anti-RBD response after both natural infection & several SARS-CoV-2 vaccines. 1/
Presence of IgG4 & IgE in COVID-19 suggests that the virus may induce an “allergic-like” response to evade immune surveillance, leading to a shift from Th1 to Th2 cells, which promotes tolerance to the virus & potentially contributes to chronic infection & may be LongCovid 2/
An increase in IgG4 levels is typically associated w/ immunological tolerance & develops after prolonged exposure to antigens. While tolerance to an allergen benefits the host in Allergen Immunotherapy, in viral infection, it enables viral persistence rather than clearance 3/